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Currently, no consensus on the ex-
act implementation of kinetic modeling 
of subtle BBB leakage has been reached 
and in vivo validation remains diffi-
cult. Some of the suggested corrections 
would influence the numerical values, 
but the group effects and conclusion 
of increased BBB leakage in Alzheimer 
disease will remain the same, which is 
confirmed by another research site (10).
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Second, and more importantly, neu-
rotoxicity assessments were not speci-
fied, making comparison with indepen-
dent studies impossible. Stereological 
evaluation would allow quantification of 
neuronal cell number and volume (4). 
Furthermore, only standard hematoxy-
lin-eosin (H-E) stains were mentioned, 
which have limited sensitivity in detect-
ing subtle changes associated with po-
tential gadolinium-related neurotoxicity 
such as impaired mitochondrial function 
(5). Assessment of pathologic chang-
es on this level would require methods 
such as lactate dehydrogenase immuno-
reactivity or electron microscopy. In ad-
dition, it is known that glial cells react 
to neurotoxic events (6), and previous 
studies found gadolinium to be depos-
ited mostly within or in close proximity 
to the endothelial wall (7). Therefore, a 
critical evaluation of potential gadodi-
amide-related neurotoxicity should in-
clude quantitative measures of reactive 
astrogliosis and microglial activation. 
While not strictly required for toxico-
logic assessments according to current 
guidelines (3), we believe that a state-
ment like the one made by Dr Smith 
and colleagues would need to be based 
on appropriate evaluation and quantifi-
cation of neuronal function.
In addition, gadolinium is regularly 
used in conditions with an impaired 
blood-brain barrier, leading to a differ-
ent risk profile for gadolinium accumu-
lation. For example, we and other inves-
tigators recently provided evidence of 
gadolinium deposition in patients with 
multiple sclerosis within routine clinical 
care (8). In conclusion, we do not be-
lieve that the shown representative nor-
mal -ppearing H-E images alone exclude 
gadolinium-related neurotoxicity, espe-
cially in conditions with potentially in-
creased gadolinium uptake in the brain.
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Editor:
We read with great interest the article by 
Dr Smith and colleagues on accumulation 
and partial clearance of gadolinium from 
the brain after repeated administration 
of gadodiamide in a rodent model with 
intact blood-brain barrier, which was re-
cently published online in Radiology (1). 
The authors state that there was no “de-
tectable neurotoxicity” and no “histopath-
ologic consequence” after up to 20 doses 
of intravenously administered gadodi-
amide with a cumulative dose of up to 
12 mmol/kg. While it is certainly encour-
aging that the authors could not detect 
any extensive tissue damage, we are con-
cerned that the histopathologic assess-
ment limits such conclusions.
First, contrary to guidelines for tox-
icologic histopathology, pathologists 
were not made aware of the different 
treatment groups, as is recommended 
for evaluations where a known toxic 
syndrome with a defined spectrum of 
lesions does not exist (2,3).
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We thank Dr Schlemm and colleagues 
for their interest in our article and ac-
knowledge the points they raise. We 
acknowledge that the current lack of 
reported neurotoxicity associated with 
brain gadolinium levels reported to 
date in both clinical and nonclinical 
studies is not definitive proof of ab-
sence of neurotoxicity and that if there 
are neurologic effects of gadolinium at 
the low levels measured they could be 
subtle in nature. We also acknowledge 
there are limitations with a standard 
H-E toxicologic assessment of central 
nervous system tissue but considered 
that it is an important first step, as 
is the case in standard drug develop-
ment, to conduct a study of this type 
in the controlled setting of a nonclini-
cal model with superior tissue preser-
vation and morphology afforded by the 
methods employed. We also recognize 
the benefits and risks of blinded his-
topathologic assessments. For clarity, 
the independent histopathologic assess-
ment was conducted masked to individ-
ual animal group assignment to avoid 
bias in our small cohort, but not to the 
agents used. The pathologist was then 
unmasked to groupings to enable inter-
pretation and reporting.
We concur that it is important to 
systematically assess the potential risk 
of gadolinium presence in the central 
nervous system and are undertaking 
further studies to detect potential sub-
tle lesions or functional deficits that 
may have no overt histologic footprint. 
Such studies will include more detailed 
tissue examination, such as ultrastruc-
ture with transmission electron mi-
croscopy, detailed behavioral assess-
ments, and other analytic techniques 
as appropriate. Proving a potentially 
negative finding requires a high stan-
dard of rigor with a weight of evidence 
approach and multiple studies and/
or techniques may be required. Con-
sidering gadolinium has been detect-
ed in the brain postmortem following 
administration of all types of contrast 
agent (both linear and macrocyclic) 
(1–3), it is important that all agents 
are assessed in a systematic way for 
potential impact.
We also acknowledge that a healthy 
animal with an intact blood-brain bar-
rier cannot replicate the varied co-mor-
bidities and underlying conditions of 
the clinic but is likely to be an invalu-
able tool in elucidating mechanisms of 
transport into the brain and action of 
any potential toxicity free of confound-
ing underlying disease states.
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